简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
29
2023-12
Voluntary Announcement Voluntary Lock-up Undertakings by Certain Shareholders
27
2023-12
Both BA1105 and BA1301 Being Granted Orphan Drug Designations for Treatment of Pancreatic Cancer by the FDA
22
2023-12
Finance Lease Agreement
12
2023-12
Resignation of Non-Executive Director
12
2023-12
List of Directors and their Roles and Functions
01
2023-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
03
2023-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
30
2023-10
Voluntary Announcement First Patient Enrolled in Phase III Clinical Trial of Nivolumab Injection (BA1104) in China
10
2023-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
21
2023-09
2023 Interim Report
5
6
7
8
9
Follow me
鲁公网安备37069102000284